Kelly Thomas Patrick Buys 7,500 Shares Amid Volatility, Signaling Confidence in Gene‑Therapy
Inside CFO Kelly Thomas Patrick’s 7,500‑share purchase shows confidence in a gene‑therapy firm amid sharp stock decline—why her buying matters for investors.
3 minutes to read